Enhanced Tacrolimus Efficacy in Psoriasis with Innovative Transethosomes: A Promising Preclinical Study on Wistar Rats. DOI
Vishwanath A Jadhav, Kishori P. Sutar,

Sankalp S. Sammasagi

и другие.

Drug Development and Industrial Pharmacy, Год журнала: 2025, Номер unknown, С. 1 - 21

Опубликована: Март 27, 2025

This study focuses on the formulation and evaluation of Tacrolimus-loaded transethosomes, which are then incorporated into a gel for topical application. The goal is to achieve deeper transdermal penetration, enhancing treatment regimen. Transethosomes were formulated using cold method optimized 32 factorial design (DESIGN EXPERT® Software) different concentrations lipid ethanol. They characterized vesicle size, entrapment efficiency, zeta potential, polydispersity index. batch was carbopol 940 base. In vitro ex vivo permeation studies carried out determine diffusion release pattern. Skin irritancy in imiquimoid-induced anti-psoriatic activity Wistar rats. F1 batch, by low concentration ethanol lipids, demonstrated size 168 nm, an efficiency 85%, potential -36mV, index 0.12. indicated 85.32% drug 76.34% after 24 hours. adhered zero-order kinetics, with Korsmeyer-Peppas model suggesting non-Fickian mechanism. transethosomal imiquimod-induced psoriasis-like rat significant therapeutic effects within seven days. Histopathological analysis showed reduced hyperkeratosis, epidermal hyperplasia, inflammation, fewer inflammatory cells dermis. Stability tests confirmed formulation's integrity at 4 °C 25 over 90 study's outcome revealed that tacrolimus-loaded transethosomes could effectively manage psoriasis.

Язык: Английский

Hyaluronic-Acid-Functionalized Tofacitinib Loaded Transethosomes for Targeted Drug Delivery in Rheumatoid Arthritis DOI

Pavani Chowdary,

Eswara Rao Puppala,

Chandra Lekha Putta

и другие.

ACS Applied Bio Materials, Год журнала: 2025, Номер unknown

Опубликована: Янв. 28, 2025

The Janus kinase inhibitor tofacitinib (TOF) is an FDA-approved drug for rheumatoid arthritis (RA) treatment, but its long-term oral use leads to significant systemic side effects. present research aimed conquer these challenges by formulating hyaluronic-acid-coated transethosomes (HA-TOF-TE), a novel system targeted, topical delivery of TOF reduce toxicity and improve therapeutic efficacy. Transethosomes were synthesized via the cold sonication technique with HA functionalization enabling CD44 receptor-mediated targeting inflamed synovial tissue. Optimized TOF-TE HA-TOF-TE formulations showed particle sizes 199.08 ± 4.2 151.5 5.4 nm, zeta potentials -27.1 0.75 -34.10 0.89 mV, entrapment efficiencies 81.16 0.84% 79.19 2.65%, respectively. gels assessed through in vitro release, ex vivo permeability, effectiveness experiments using Freund's complete adjuvant (CFA) model. Ex studies 2.02-fold 1.61-fold increments flux HA-TOF-TE, respectively, superior skin retention HA-TOF-TE. In efficacy confirmed HA-TOF-TE's (P < 0.001) anti-inflammatory effect on arthritic rat paws, outperforming FD gels. Cytokine analysis notable reductions serum IL-1, IL-6, PGE-2 levels after closely approximating control values. Additionally, mRNA demonstrated marked decreases CD44, collagen II expression, indicating potential as effective, targeted RA addressing conventional therapy minimizing

Язык: Английский

Процитировано

0
Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis DOI Creative Commons
Yuanyuan Li,

Yiheng Cheng,

Yuchen Cai

и другие.

Biomedicines, Год журнала: 2025, Номер 13(4), С. 781 - 781

Опубликована: Март 23, 2025

Psoriasis is an immune-related disorder that marked by abnormal thickening of the skin, rapid multiplication keratinocytes, and complex interactions between immune cells affected areas. Although psoriasis cannot currently be cured, drugs can alleviate symptoms regulating homeostasis preventing comorbidities. There are many types to treat psoriasis: small-molecule drugs, including corticosteroids; retinoids; vitamin D analogs; immunosuppressants, such as glucocorticoid ointment, tretinoin cream, methotrexate tablets, etc. Macromolecular biological Certolizumab, Secukinumab, Guselkumab, etc., include monoclonal antibodies target various inflammatory signaling pathways. Compared with traditional therapies offer better targeting lower systemic side effects, but their high costs invasive administration modes constrict widespread use. Spesolimab latest agent used interleukin-36 receptor (IL-36R) approved for market use, which significantly reduces risk general pustular (GPP) flare 84%. Additionally, there several agents interleukin-23/T helper 17 cell pathway have already entered Phase II III clinical trials. At present, first-line therapeutic strategy mild topical administration. Systemic therapy phototherapy preferred treating moderate severe types. However, current completely meet needs. More advanced drug delivery systems optimized effects bioavailability required. Nanocarriers emerging proteins, nucleic acids, cell-based therapies. In this review, we analyze status therapeutics discuss novel diverse well We also summarize effectiveness different strategies.

Язык: Английский

Процитировано

0
Enhanced Tacrolimus Efficacy in Psoriasis with Innovative Transethosomes: A Promising Preclinical Study on Wistar Rats. DOI
Vishwanath A Jadhav, Kishori P. Sutar,

Sankalp S. Sammasagi

и другие.

Drug Development and Industrial Pharmacy, Год журнала: 2025, Номер unknown, С. 1 - 21

Опубликована: Март 27, 2025

This study focuses on the formulation and evaluation of Tacrolimus-loaded transethosomes, which are then incorporated into a gel for topical application. The goal is to achieve deeper transdermal penetration, enhancing treatment regimen. Transethosomes were formulated using cold method optimized 32 factorial design (DESIGN EXPERT® Software) different concentrations lipid ethanol. They characterized vesicle size, entrapment efficiency, zeta potential, polydispersity index. batch was carbopol 940 base. In vitro ex vivo permeation studies carried out determine diffusion release pattern. Skin irritancy in imiquimoid-induced anti-psoriatic activity Wistar rats. F1 batch, by low concentration ethanol lipids, demonstrated size 168 nm, an efficiency 85%, potential -36mV, index 0.12. indicated 85.32% drug 76.34% after 24 hours. adhered zero-order kinetics, with Korsmeyer-Peppas model suggesting non-Fickian mechanism. transethosomal imiquimod-induced psoriasis-like rat significant therapeutic effects within seven days. Histopathological analysis showed reduced hyperkeratosis, epidermal hyperplasia, inflammation, fewer inflammatory cells dermis. Stability tests confirmed formulation's integrity at 4 °C 25 over 90 study's outcome revealed that tacrolimus-loaded transethosomes could effectively manage psoriasis.

Язык: Английский

Процитировано

0